EP Patent

EP3790535A1 — Combinations of beta-lactam compounds and probenecid and uses thereof

Assigned to Iterum Therapeutics International Ltd · Expires 2021-03-17 · 5y expired

What this patent protects

The present disclosure relates to bilayer tablets comprising a second layer comprising a β-lactam compound or a pharmaceutically acceptable salt thereof; and a first layer comprising probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to …

USPTO Abstract

The present disclosure relates to bilayer tablets comprising a second layer comprising a β-lactam compound or a pharmaceutically acceptable salt thereof; and a first layer comprising probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease using the bilayer tablets.

Drugs covered by this patent

Patent Metadata

Patent number
EP3790535A1
Jurisdiction
EP
Classification
Expires
2021-03-17
Drug substance claim
No
Drug product claim
No
Assignee
Iterum Therapeutics International Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.